Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologyProtocol groupLymphomas (ped.)DiseaseHodgkin LymphomaSubgroupICD10C81.-MeSHHodgkin DiseaseSequencePAED EuroNet-PHL-C2, Hodgkin, TL-1PAED EuroNet-PHL-C2, Hodgkin, TL-2PAED EuroNet-PHL-C2, Hodgkin, TL-3ChemotherapyChemo-substanceCyclophosphamideDacarbazineDoxorubicinEtoposidePembrolizumabPrednisoloneVincristineChemo-substanceCyclophosphamideDacarbazineDoxorubicinEtoposidePembrolizumabPrednisoloneVincristineChemo-substanceCyclophosphamideDacarbazineDoxorubicinEtoposidePembrolizumabPrednisoloneVincristineChemo-substanceCyclophosphamideDacarbazineDoxorubicinEtoposidePembrolizumabPrednisoloneVincristineNo. Substances146 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleFosaprepitantGranisetronMesnaNo. Substances15Protocol classificationTherapy classificationalternativeStudy protocol, currentIntensityStandard doseTherapy indicationFirst lineRelapse therapyTherapy phaseTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlColitisEmetogenicity (MASCC/ESMO)HypertensionHyperthyroidismHypothyroidismNeutropeniaPneumonitisPruritusRash only studiesPublicationAuthorGeoerger BKörholz DDiseaseFortgeschrittenes, refraktäres oder rezidiviertes Hodgkin Lymphom, 0,5-17 Jahre, Lansky Score größer 50Neudiagnostiziertes Hodgkin Lymphom im Kindes- und JugendalterOriginDepartment of Paediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Villejuif, France, Keynote-051European Network-Paediatric Hodgkin’s Lymphoma Study Group (EuroNet-PHL)Protocols in Revision 3 protocols foundPAED EuroNet-PHL-C2, COPDAC-28, Hodgkin Lymphoma (PID1279 V1.0)PAED EuroNet-PHL-C2, DECOPDAC-21, Hodgkin Lymphoma (PID1239 V1.0)PAED Pembrolizumab 2, Hodgkin Lymphoma (PID2978 V1.0)
